

#### PATENT COOPERATION TREATY

From the

INTERNATIONAL PRELIMINARY EXAMINING

To:

KIM, Scog-Hyun

9th Floor, Dackyung Bldg., 120, 2-ka Tacpyung-ro, Chung-ku, 100-724 Scoul, Republic of Korea

PCT

NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing

(day/month/year) 25 OCTOBER 2004 (25.10.2004)

Applicant's or agent's file reference

OP03-1029

IMPORTANT NOTIFICATION

International application No.

International filing date (day/month/year)

Priority date (day/months/year)

PCT/KR2003/001301

02 JULY 2063 (02.07.2003)

02 JULY 2002 (02.07.2002)

Applicant

GENOMINE INC. et al

- 1. The applicant is hereby notified that International Preliminary Examining Authority transmits here with the international preliminary examination report and its annexes, if any, established on the international application.
- 2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report/but not of any annexes) and will transmit such translation to those Offices.

### 4. REMINDER

The applicant must enter the national phase before each elected office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details in the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/KR

Republi

Korcan Intellectual Property Office 920 Dunsan-dong, Seo-gu, Daejeon 302-701, Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

COMMISSIONER


Telephone No. 82-42-481-5207



# Rec'c PCT/PTO 3 0 DEC 2004

### ATENT COOPERATION TREATY

## **PCT**




### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Artcle 36 and Rule 70)

		<del></del>					
Applicant's or agent's file reference OP03-1029  FOR FURTHER ACT		SeeNotificationofTransmittalofInternationalPreliminary Examination Report (Form PCT/IPEA/416)					
International application No.	International filing date(day)	(month/year)	Priority date (day/month	/year)			
PCT/KR2003/001301	02 JULY 2003 (02.07	2003)	02 JULY 2002 (02.07.2	002)			
International Patent Classification (IPC) IPC7 C12N 9/10  Applicant GENOMINE INC. et al  1. This international preliminary exand is transmitted to the applican	camination report has been pr		ernational Preliminary Exar	nining Authority			
2. This REPORT consists of a total	2. This REPORT consists of a total of 4 sheets, including this cover sheet.						
This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).  These annexes consist of a total ofsheets.							
This report contains indications relating to the following items:  I X Basis of the report  II Priority  Non-establishment of opinion with regard to novelty, inventive step and industrial applicability  IV Lack of unity of invention  V X Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement  VI Certain documents cited  VII Certain defects in the international application  VIII Certain observations on the international application							
Date of submission of the demand	· D	ate of completion o	of this report				
02 FEBRUARY 2004	(02.02.2004)	20 OCTOB	ER 2004 (20.10.2004)				
Name and mailing address of the IPEA	KR A	uthorized officer					
Korean Intellectual Propert 920 Dunsan-dong, Seo-gu, Republic of Korea	y Office Daejeon 302-701,	CHO, YOUNG	G GYUN	(NOTE )			
Facsimile No. 82-42-472-7140	Т	elephone No. 82-4	42-481-8132	130100			





I.	Basis	of the report						
1.	With	regard to the elements of the international application:*						
	X	the international application as originally filed						
		the description:						
		pages pages	, as originally filed , filed with the demand					
		pages, filed with the letter of						
	$\Box$	the claims:						
	_	pages, as amended (together with an	, as originally filed					
		pages , as amended (together with an	, filed with the demand					
		pages, filed with the letter of						
		the drawings:						
		pagespages	, as originally filed , filed with the demand					
		pages, filed with the letter of						
		the sequence listing part of the description:						
		pagespages	, as originally filed , filed with the demand					
		C1. 1						
2.	the	the regard to the language, all the elements marked above were available or furnished to this Authority international application was filed, unless otherwise indicated under this item. See elements were available or furnished to this Authority in the following language <u>Engl</u> the language of a translation furnished for the purposes of international search (under Rule 23 the language of publication of the international application (under Rule 48.3(b)). the language of the translation furnished for the purposes of international preliminary examor 55.3).	which is .1(b)).					
3		th regard to any nucleotide and/or amino acid sequence disclosed in the international application was carried out on the basis of the sequence listing:  contained inthe international application in written form.  filed together with the international application in computer readable form.  furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readable form  The statement that the subsequently furnished written sequence listing does not go be international applicationas as filed has been furnished.  The statement that the information recorded in computer readable form is identical to the been furnished.	eyond the disc losure in the					
5.		The amendments have resulted in the cancellation of:  the description, pages the claims, Nos.  the drawings, sheet  This report has been established as if (some of) the amendments had not been made, since go beyond the disclosure as filed, as indicated in the Supplemental Box(Rule 70.2(c)).**						
*	* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed." and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).							
	** Any replacement sheet containing such amendments must be referred to under item I and annexed to this report.							

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability	;
citations and explanations supporting such statement	

1. Statement			
Novelty (N)	Claims	5-9, 12-19	YES
	Claims	1-4, 10-11	N0
Inventive step (IS)	Claims	17-19	YES
michanic stop (20)	Claims	5-9, 12-16	NO
Industrial applicability (IA)	Claims	1-19	YES
	Claims	None	

2. Citations and explanations (Rule 70.7)

The following documents have been considered for the purpose of this report:

D1: GenBank Accession No. T48458, 20 APRIL 2000

D2: US 5,477,001 A (ELF SANOFI et al.) 19 December 1995

D1 discloses a 8-amino-7-oxononanoate synthase-like protein having 469 amino acids, isolated from *Arabidopsis thaliana*.

D2 discloses a protein having beta-1,3-glucanase activity; a DNA construct encoding said protein; a plant cell transformed with said DNA construct; a plant or plant seed transformed with said DNA construct; and a method for preparing said protein.

### I. Novelty

Claims 1-4 and 10-11 relate to an isolated polypeptide having an amino acid sequence of SEQ. ID NO. 2; an isolated polynucleotide encoding said polypeptide; and an antisense polynucleotide complementary to said polynucleotide. D1 discloses a 8-amino-7-oxononanoate synthase-like protein isolated from *Arabidopsis thaliana*, having 469 amino acids identical to SEQ. ID NO. 2 in the present invention.

Therefore, claims 1-4 and 10-11 in this invention are not considered to be novel under PCT Article 33(2).

(Continued on Supplemental Sheet.)

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of:

Box V.

### II. Inventive Step

Claims 5-9 and 12-16 relate to an expression vector comprising the polynucleotide of claim 3 or the antisense polynucleotide of claim 10; a cell comprising said expression vector; and a transgenic plant or a seed comprising said expression vector.

D1 discloses a 8-amino-7-oxononanoate synthase-like protein having 469 amino acids identical to SEQ. ID NO. 2 in the present invention. D2 discloses a DNA construct encoding the protein having beta-1,3-glucanase activity, a plant cell transformed with said DNA construct; and a plant or plant seed transformed with said DNA construct. The present invention is obvious to a person skilled in the art from the disclosure of D1 and D2.

Therefore, claims 5-9 and 12-16 in this invention lack an inventive step under PCT Article 33(3) as being obvious in view of D1 and D2.

III. Industrial Applicability

The subject matter of claims 1-19 is considered to be industrially applicable under Article 33(4) PCT.